ID: ALA1090708

Max Phase: Preclinical

Molecular Formula: C21H35NO

Molecular Weight: 317.52

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCCCCCCc1ccc2c(c1)CC[C@H]([C@@](C)(N)CO)C2

Standard InChI:  InChI=1S/C21H35NO/c1-3-4-5-6-7-8-9-17-10-11-19-15-20(21(2,22)16-23)13-12-18(19)14-17/h10-11,14,20,23H,3-9,12-13,15-16,22H2,1-2H3/t20-,21-/m0/s1

Standard InChI Key:  FDWNCOPDJMZWAI-SFTDATJTSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 317.52

Molecular Weight (Monoisotopic): 317.2719

AlogP: 4.40

#Rotatable Bonds: 9

Polar Surface Area: 46.25

Molecular Species: BASE

HBA: 2

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 2

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 9.97

CX LogP: 5.52

CX LogD: 3.08

Aromatic Rings: 1

Heavy Atoms: 23

QED Weighted: 0.66

Np Likeness Score: 0.46

References

1. Ma B, Guckian KM, Lin EY, Lee WC, Scott D, Kumaravel G, Macdonald TL, Lynch KR, Black C, Chollate S, Hahm K, Hetu G, Jin P, Luo Y, Rohde E, Rossomando A, Scannevin R, Wang J, Yang C..  (2010)  Stereochemistry-activity relationship of orally active tetralin S1P agonist prodrugs.,  20  (7): [PMID:20188554] [10.1016/j.bmcl.2010.02.006]

Source

Source(1):

• Scientific Literature